Chinese medicine injection limit companies under pressure China Resources 39 and other products sales decline

The pressure of national medical insurance fee control continues, and medical institutions increase the monitoring of auxiliary drug use, which has an impact on the market sales of Chinese medicine injections.
recently, China Resources 39, Lizhu Group and other pharmaceutical companies in the investor relations activity records disclosed that the company's sales of Chinese medicine injections under pressure.
re-evaluation of Chinese medicine injections has been the concern of the industry, many enterprises also hope to use Chinese medicine injections to re-evaluate the effectiveness of self-tested drugs. "In recent years, there has been a lot of controversy over Chinese medicine injections, and their adverse reactions have changed the market." An analyst in the pharmaceutical industry told reporters that it is necessary to start the re-evaluation of such drugs, which is also beneficial to the long-term development of Chinese medicine injections.
recently, the Director General of the State Drug Administration, Jia Hong, went to the Chinese Academy of Traditional Chinese Medicine to listen to the opinions and suggestions of experts on the supervision of Chinese medicine, which involves Chinese medicine injections. Whether the re-evaluation of Chinese medicine injections can be started in 2018 has once again aroused market concern.
, however, yesterday, an industry insider told reporters that the industry is still controversial about whether to start the re-evaluation of Chinese medicine injections.pharmaceutical companies related products under pressure
under the pressure of medical insurance charges, many began to establish a key monitoring drug system, some regions even published a list of key monitoring drugs. Among them, Chinese medicine injection has become the focus of monitoring objects.
China Resources 39 official website shows that the company's prescription Chinese medicine prescription drugs include included injections, Huayusin products, serum injections, ginseng injections, pulse injections and so on. China Resources said in a recently released record of investor relations activities, Chinese medicine injections as a proportion of total revenue has declined, about 8%, but in terms of profit contribution, accounting for more than 10%. The Chinese medicine injection and auxiliary drug market has been generally affected by the overall environmental impact, the first quarter performance is lower than expected, the long-term is not optimistic, the future may be a small decline, is currently stabilizing the market size. In addition, China Resources' 392017 Annual Report shows that during the reporting period, actual sales of Chinese medicine injection products declined in the face of policy pressure and tender price reductions.
Not unique, Lizhu Group recently in the investor relations activity record table, in the past two years, many Chinese medicine injections have been affected by medical reform policies, tender price reduction, especially from the fourth quarter of 2017, superimposed on the new version of health insurance and drug proportion pressure, the injection in some hospitals under greater pressure, in the first quarter of 2018, the variety of income of 24.7% decline.The chinese medicine injection enterprises seek change
for the Chinese medicine injection market sales affected, the above-mentioned industry believes that the formulation of national policies does not necessarily mean that it can be implemented on the ground. Chinese medicine injection enterprises still have room for survival.
, however, how companies respond to market and policy changes remains a concern for investors.
Lizhu Group in the exchange with investors, said that the follow-up, the company will do a good job in the following aspects of sales promotion: First, will continue to increase marketing efforts, one is to pull up the sale of low-yielding third-level hospitals; This part of the medical insurance injections on the hospital level restrictions, will be to a certain extent conducive to the company's varieties to the primary hospital sinking; Further, the company disclosed that the company is obtaining clinical approval in the United States, the company will continue to carry out clinical research in the United States, but also will continue to carry out the variety in the domestic post-market research, hope that more doctors and patients can fully realize the effectiveness and safety of ginseng.
it is worth mentioning that through the development of post-market research and re-evaluation work has become an important way for Chinese medicine injection enterprises to prove the effectiveness of their products.
, the national version of the programme of work on the re-evaluation of Chinese medicine injections has not yet been made public. Judging from the news released so far, the relevant departments of the state have been pushing this matter.
last year, Bi Jingquan, the former head of the State Food and Drug Administration, said that the evaluation of the consistency of drug quality and efficacy should be accelerated, and the re-evaluation of the safety and efficacy of Chinese medicine injection drugs should be initiated.
March 2018, the 2017 Annual Drug Review Report was released to the public, which mentions that the focus of the PDR center in 2018 includes research to initiate the re-evaluation of Chinese medicine injections and the development of technical guidelines for re-evaluation.
afternoon of May 22, the director of the State Drug Administration, Jia Hong, went to the Chinese Academy of Traditional Chinese Medicine to communicate with the Society and listen to experts' opinions and suggestions on the supervision of Chinese medicine, according to the website of the State Drug Administration. Experts from clinical, scientific research and industry discussed deepening the reform of the drug review and approval system and strengthening the supervision of Traditional Chinese medicine, and made constructive suggestions on the re-evaluation of Chinese medicine injections, the supervision of Chinese medicine tablets and Chinese medicine formula particles, and the proper handling of historical legacies such as the promotion of landmarks. He expressed the hope that the Society will establish a cooperative mechanism to jointly promote the establishment of a more consistent with the law of the development of Chinese medicine review and approval and supervision system, and promote the high-quality development of Chinese medicine.
, the above-mentioned industry insiders in an interview with reporters, said that the re-evaluation of Chinese medicine injections involved more stakeholders, the industry's attitude on the matter is not consistent. Therefore, the promotion of this matter also faces some difficulty. (Securities Daily)